Direct answer: On September 3, 2026, the FDA released the Botanical Drug Products Information Request (RFI) for advice on development challenges and potential forms of scientific support. It is an open consultation, is not a new regulation, is a final guide, and does not represent the new plant medicine review requirements identified by the FDA. The FDA bulletin sets the deadline for comments at 3 November 2026.The nature of the document, its current status and the business proposals are set out below; Specific products should be judged in the official language.
What is this file, at what stage?
The regulatory document and its status referred to in this paper is based on the original FDA page listing. RFI is a request for information and is not a rule or has established a review standard; This observation does not represent that FDA has accepted a recommendation.
A distinction should be made between binding regulations/final rules and FDA guides, drafts, discussion papers or enforcement policies. The latter have different legal effects; Specific sources of restraint are governed by the documents and by the legislation cited.
Which enterprises and products need attention?
Developers of plant medicine products, suppliers of raw materials, quality and clinical development teams.
It is recommended that this be confirmed on a product-business role-US market-based basis; Where product classifications or responsible subjects cannot be judged by name alone, the labels are subject to individual checks.
Where is the change from what was previously requested?
The substance of the document and the background to the previous rules are set out below. Only changes specified in official documents are considered to be changes; The recommendatory content is not to be added to the mandatory obligation.
Direct answer:On September 3, 2026, the FDA released the Botanical Drug Products Information Request (RFI) for advice on development challenges and potential forms of scientific support. It is an open consultation, is not a new regulation, is a final guide, and does not represent the new plant medicine review requirements identified by the FDA. The deadline for the opinion set out in the FDA Bulletin is 3 November 2026.
The FDA would like to know the obstacles in the development of plant medicines and possible scientific solutions, including quality standards for complex plant mixtures, appropriate research design, real world evidence and other credible scientific information, as well as the potential need for updating existing guidelines and resources.
- It is established whether the product is intended for use or labeled as a diagnosis, treatment or prevention of disease.
- Combination of plant sources, material and composition complexity, batch consistency, production control and quality information.
- Identify the current product development stage and whether development is to follow the FDA drug application path.
- Access to the RFI original text and public docket; If comments are submitted, they should follow the official channels of submission and deadlines.
As of the date of the reconciliation, the FDA page was used as an RFI public consultation and the comment period was still ongoing and was scheduled to close on 3 November 2026. The potential directions mentioned in the consultation should not be written into existing mandatory requirements; The enterprise should continue to advance the project in accordance with the applicable legislation and the official guidelines issued by the FDA.
Key dates and transitional arrangements
The following dates are derived from the factual summary of the documents retained here. A distinction should be made between the date of issuance, the date of closure of comments and the date of entry into force/application of the respective documents. There is no presumption in respect of matters that are not clearly stated in the original text.
- 3 September 2026: Date of issuance of the document (as expressed in the original language of the adjacent official).
- 3 November 2026: Comments/due date of submission (as expressed in the original language of the neighbouring Government).
The date of publication/update of the website’s articles does not correspond to the date of implementation of the statute; If the dates of the official pages differ, reference is made to the official document and the current FDA page.
How can Chinese companies prepare?
- Collating plant sources, species identification, feedstock and process control, batch consistency, research design and safety evidence; Tracks FDA's follow-up to RFI.
- Identify those responsible, sources and internal review nodes, and maintain official page versions and verification dates.
- If the official document is revised, withdrawn or the final version issued, the applicable conclusions are reassessed and the records updated.
For this purpose, the recommendation does not substitute for the obligation set out in the body of the statute.
Exceptions, pending confirmations and common misreading
- RFI is a request for information and is not a rule or has established a review standard; This observation does not represent that FDA has accepted a recommendation.
- When exemptions, transition periods, border products or different business actors are encountered, the original text should be consulted on the basis of specific facts; Uncertainties should be clearly identified for confirmation.
- Registration, listing, submission or obtaining of a reply should not be mistakenly referred to as FDA approval or authentication.
Official information and reconciliation records
(b) The station’s author: Mr. Toshito. Reviewer: Mr. Toto. Date of the structural review of the article: 2026-11-02; The statutory status and specific obligations are based on the official language listed.
Next
Identification of scope of application by product and corporate role, viewing Regulatory UpdatesAnd the corresponding FDA Compliance Service Scope; If you need a case judgement, you can do it. Contact PageSubmission of product information.